Trials / Completed
CompletedNCT00171977
Post-Marketing Clinical Study of Postoperative Adjuvant Therapy With Imatinib Mesylate in Patients With Gastrointestinal Stromal Tumors (GIST)
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 64 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 20 Years – 74 Years
- Healthy volunteers
- Not accepted
Summary
This is a multicenter, post-marketing, clinical study evaluating the safety and efficacy of postoperative adjuvant therapy with Imatinib Mesylate in high-risk patients after curative resection of newly diagnosed GIST.Patients will be evaluated for relapse -free survival as measured by the confirmation of tumor recurrence and survival for 3 years after surgery for their primary tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Imatinib Mesylate |
Timeline
- Start date
- 2004-07-01
- Primary completion
- 2009-04-01
- First posted
- 2005-09-15
- Last updated
- 2012-08-07
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT00171977. Inclusion in this directory is not an endorsement.